Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
NCT02106104
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes
Interventions
DRUG:
Linagliptin 5 mg QD (N=24)
DRUG:
Glimepiride 1 mg QD (N=24)
Sponsor
Amsterdam UMC, location VUmc